I

(redirected from Hodgkin's disease)
Also found in: Dictionary, Thesaurus, Medical, Legal, Acronyms, Encyclopedia, Wikipedia.
Related to Hodgkin's disease: Huntington's disease

I

Fifth letter of a Nasdaq stock symbol specifying that it is the third preferred bond of the company.

I

1. On a stock transaction table, a symbol indicating that a dividend was paid after a stock split.

2. A symbol appearing next to a bond listed on NASDAQ indicating that the bond is a company's third preferred bond. All NASDAQ listings use a four-letter abbreviation; if the letter "I" follows the abbreviation, this indicates that the security being traded is a third preferred bond.

i

Used in the dividend column of stock transaction tables to indicate that the dividend was paid after a stock dividend or split: Lehigh s.20i.
Mentioned in ?
References in periodicals archive ?
Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial.
The bo- ne marrow in Hodgkin's disease - a two year study.
Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. J Nati Cancer Inst 2002;94:182-92.
Treatment modalities for individuals with Hodgkin's disease are based on age, classification and the overall condition of the patient.
The relative risk for cardiovascular disease is about two- to sevenfold higher in Hodgkin's disease survivors compared with age- and gender-matched people with no cancer history.
The incidence of other leukemias and Hodgkin's disease decreased significantly, to 3.6% and 0.7%, respectively.
His sister is undergoing radiotherapy treatment for Hodgkin's disease, a form of leukaemia.
From travelling in the South during segregation, to being an identical twin, or surviving Hodgkin's disease, you can listen to excerpts from fascinating stories and browse the audio clips.
Donations can be made for research into Hodgkin's Disease through the Paula Batey Fund, care of Lloyds TSB bank, Bellingham.
"We are pleased with our partnership with BioWa and with its technology as a method for increasing the potency of MDX-1401, a novel product that broadens our anti-CD30 clinical program for Hodgkin's disease."
TWENTY years on from the tragic death of 21- year-old Paula Batey from Hodgkin's disease, a fund set up in her name has raised more than pounds 100,000 for research.